A Hunter led prostate cancer trial has yielded promising clinical results using hormone therapy to impede testosterone levels in conjunction with radiotherapy.
Toxicity and quality of life effects were studied in one thousand men across 23 cancer centres in Australia and New Zealand between 2003 and 2007.
The initial findings of the Randomised Androgen Deprivation and Radiotherapy trial have been published in the Lancet Oncology journal.
